ERAS - Erasca forms clinical trial partnership with Pfizer for cancer therapy
- The clinical-stage biotech Erasca, Inc. ( NASDAQ: ERAS ) and Pfizer ( PFE ) announced an agreement on Thursday to jointly investigate a cancer therapy combining the former’s experimental therapy, ERAS-007, and PFE’s blockbuster breast cancer therapy Ibrance.
- As part of the clinical trial collaboration and supply agreement, the companies will test Ibrance, also known as Palbociclib, in combination with ERAS-007 in a proof-of-concept study for colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) with certain genetic mutations.
- The therapeutic combination is currently being studied in a Phase 1b/2 HERKULES-3 master protocol study for gastrointestinal (GI) malignancies, sponsored by ERAS with Palbociclib supplied from PFE at no cost.
- ERAS-007 is an ERK1/2 inhibitor, and Ibrance is a CDK4/6 inhibitor. The latter added $5.4B to Pfizer’s ( PFE ) topline in 2021.
For further details see:
Erasca forms clinical trial partnership with Pfizer for cancer therapy